Drug Trial Radar · NCT06796907
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
305
Planned (sponsor's estimate)
Start
Mar 4, 2025
Primary completion
Jun 21, 2027
Study completion Oct 10, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns. Researchers are developing new treatments that combine different medicines for those who do not respond to single medicine. This study is looking at how safe and tolerable Mocertatug Rezetecan (Mo-Rez) is, how the body handles it, and how well it works when used with other cancer medicines. The study will include participants with advanced solid tumors who have either not responded to standard treatments or cannot tolerate them or have no available effective treatment.
Conditions
- Tumours, Gynecological
Interventions
Mo-RezDrug
Mo-Rez will be administered intravenously (IV).
DostarlimabDrug
Dostarlimab will be administered IV.
BevacizumabDrug
Bevacizumab will be administered IV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of participants with dose limiting toxicities (DLTs)Time frame: Approximately 7 months
- Part A: Number of participants with adverse events (AEs), immune-mediated adverse events (imAEs), adverse events of special interest (AESI), serious adverse events (SAEs) by SeverityTime frame: Up to approximately 22 months
- Part A: Number of participants with adverse events (AEs), immune-mediated adverse events (imAEs), adverse events of special interest (AESI), serious adverse events (SAEs) by FrequencyTime frame: Up to approximately 22 months
- Part B: Confirmed Objective Response Rate (ORR)Time frame: Up to approximately 37 months
Locations
83 sites in 23 countries. Site status is shown where the registry gives one.
GSK Investigational Site
La Jolla, California · Recruiting
GSK Investigational Site
Aurora, Colorado · Recruiting
GSK Investigational Site
Rochester, New York · Recruiting
GSK Investigational Site
Durham, North Carolina · Recruiting
GSK Investigational Site
Columbus, Ohio · Recruiting
GSK Investigational Site
Buenos Aires, Argentina · Recruiting
GSK Investigational Site
Buenos Aires, Argentina · Recruiting
GSK Investigational Site
CABA, Argentina · Recruiting
GSK Investigational Site
Viedma, Argentina · Recruiting
GSK Investigational Site
Liverpool, New South Wales, Australia · Recruiting
GSK Investigational Site
Wollongong, New South Wales, Australia · Recruiting
GSK Investigational Site
Brussels, Belgium · Recruiting
GSK Investigational Site
Ghent, Belgium · Recruiting
GSK Investigational Site
Leuven, Belgium · Recruiting
GSK Investigational Site
Liège, Belgium · Recruiting
GSK Investigational Site
Barretos, Brazil · Recruiting
GSK Investigational Site
Goiânia, Brazil · Recruiting
GSK Investigational Site
Natal, Brazil · Recruiting
GSK Investigational Site
Porto Alegre, Brazil · Recruiting
GSK Investigational Site
São Paulo, Brazil · Recruiting
GSK Investigational Site
Vitória, Brazil · Recruiting
GSK Investigational Site
Vancouver, British Columbia, Canada · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Herlev, Denmark · Recruiting
GSK Investigational Site
København Ø, Capital Region, Denmark · Recruiting
GSK Investigational Site
Helsinki, Finland · Recruiting
GSK Investigational Site
Tampere, Finland · Recruiting
GSK Investigational Site
Lyon, France · Recruiting
GSK Investigational Site
Marseille, France · Recruiting
GSK Investigational Site
Montpellier, France · Recruiting
GSK Investigational Site
Pierre-Bénite, France · Recruiting
GSK Investigational Site
Villejuif, France · Recruiting
GSK Investigational Site
Cologne, Germany · Recruiting
GSK Investigational Site
Leipzig, Germany · Recruiting
GSK Investigational Site
München, Bavaria, Germany · Recruiting
GSK Investigational Site
Mainz, Rhineland-Palatinate, Germany · Recruiting
GSK Investigational Site
Athens, Greece · Recruiting
GSK Investigational Site
Athens, Greece · Recruiting
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.